FILE:LH/LH-8K-20051208103020.txt.gz
EVENTS:	Regulation FD Disclosure
TEXT:
ITEM: Regulation FD Disclosure
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 7.01. Regulation FD Disclosure
On December 8, 2005  Laboratory Corporation of America Holdings (LabCorp) announced that it plans to sell up to $250 million aggregate principal amount of Senior Notes due 2015, pursuant LabCorp's new shelf registration statement. The Notes will be senior unsecured obligations and will rank equally with all of LabCorp's other existing and future senior unsecured debt.
Exhibits
99.1 Press Release dated December 8, 2005
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Exhibit 99.1
Laboratory Corporation of America Holdings 358 South Main Street Burlington, NC 27215 Telephone:(336) 584-5171
Investor Contact: Scott Fleming - 336-436-4879 Media Contact: Pam Sherry - 336-436-4855 Shareholder Direct: (800)LAB-0401
FOR IMMEDIATE RELEASE
Laboratory Corporation of America Holdings (LabCorp) (NYSE: LH) today announced that it plans to sell up to $250 million aggregate principal amount of Senior Notes due 2015, pursuant LabCorp's new shelf registration statement. The Notes will be senior unsecured obligations and will rank equally with all of LabCorp's other existing and future senior unsecured debt.
Burlington, NC, December 8, 2005 
LabCorp intends to use the net proceeds of the senior notes, together with cash on hand, to repay borrowings under its senior credit facility which will be used to repurchase shares of LabCorp's common stock.
The sole book-running manager of the offering is Banc of America Securities LLC. Lehman Brothers, Inc. shall be the co-manager for the offering. A copy of the prospectus and prospectus supplement meeting the requirements of Section 10 of the Securities Act of 1933 may be obtained from Banc of America Securities LLC, Prospectus Department, 100 West 33 Street, 3 Floor, New York, New York 10001 or by calling 1-800-294-1322 or e-mailing dg-prospectus-distribution@bofasecurities.com.
rd
rd
Laboratory Corporation of America Holdings and its subsidiaries, headquartered in Burlington, North Carolina, is the second largest independent clinical laboratory company in the United States based on 2004 net revenues. Through its national network of laboratories, the Company offers a broad range of clinical laboratory tests which are used by the medical profession in routine testing, patient diagnosis, and in the monitoring and treatment of disease. In addition, the Company has developed specialty and niche businesses based on certain types of specialized testing capabilities and client requirements, such as oncology testing, HIV genotyping and phenotyping, diagnostic genetics and clinical research trials.
About LabCorp


